Site Editor
Shaji K. Kumar, MD
Shaji K. Kumar, MD
Posted: Thursday, June 20, 2024
Based on the updated intention-to-treat and subgroup analyses of the phase III DREAMM-7 trial, the B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate belantamab mafodotin-blmf plus bortezomib and dexamethasone (BVd) vs standard-of-care daratumumab, bortezomib, and dexamethasone (DVd) demonstrated improved antitumor activity in patients with relapsed or refractory multiple myeloma. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 7503), Maria-Victoria Mateos, MD, PhD, of Hospital Universitario de Salamanca, Spain, and colleagues underscored the potential for BVd as a new standard of care.
Patients who underwent at least one prior line of therapy were randomly assigned in a 1:1 ratio to receive either BVd (n = 243) or DVd (n = 251). The median durations of progression-free survival were 36.6 and 13.4 months, respectively, in the intention-to-treat population. The overall (82.7% vs 71.3%) and complete (34.6% vs 17.1%) response rates were higher with BVd.
A total of 33% of the patients treated with BVd and 35% of those who received DVd were refractory to lenalidomide at baseline. In this subgroup, the overall response rate (84% vs 61%) and median progression-free survival (25.0 vs 8.6 months) were found to favor BVd over DVd. High-risk cytogenetic abnormalities were documented in 28% and 27% of the arms, respectively. Treatment with BVd conferred a higher overall response rate (85% vs 67%) and prolonged the median progression-free survival (33.2 vs 10.5 months) in this subgroup.
More deaths were reported with DVd (35%) than with BVd (22%) in the intention-to-treat population; the median overall survival was not reached in either arm. The entire population experienced an adverse event, with toxicities of grades 3 and 4 observed in 95% of the patients treated with BVd and in 76% of those who received DVd. A total of 50% and 37% of patients, respectively, had a serious adverse event. Ocular adverse events were reported more frequently with BVd (79% vs 29%).
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
